Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces adoption of RefluxStop at the world-renowned Careggi University Hospital.
The first RefluxStop® procedure at Careggi University Hospital was successfully performed by Dr. Paolo Prosperi, Chief of Emergency Surgery, assisted by Dr. Alessio Giordano. As part of the prestigious University of Florence, Careggi University Hospital is one of Italy’s most respected medical centers and a reference institution for innovative surgical technologies. Its adoption of RefluxStop® represents another strategic expansion into a major European hospital system and supports the scalable rollout of the technology across high-volume centers of excellence.
Dr. Prosperi says, “It’s very exciting to see innovation in GERD treatment on the surgical front. RefluxStop’s unique mechanism of action limits many of the undesirable side effects of traditional anti-reflux surgery, as it does not encircle the esophagus, making it an excellent surgical alternative. I am truly excited about RefluxStop’s approach to restoring the body’s natural anti-reflux barrier, which has never been possible before in the history of GERD treatment. I look forward to bringing this innovative solution to the GERD patients in the region of Tuscany and beyond, and helping to transform their quality of life.”
Inventor of RefluxStop®, CEO and founder of Implantica, Dr. Peter Forsell says, “Congratulations to Dr. Prosperi and his team on completing the first RefluxStop® procedure at the highly respected Careggi University Hospital. GERD remains a significant unmet medical need that impacts one billion people worldwide and up to 20% of Italy’s population is estimated to be suffering from GERD1.”
Dr. Forsell continues, “With more than 1,400 RefluxStop® patients treated across Europe, we continue to see strong and consistent outcomes, including in patients who previously had few effective treatment options. The adoption of RefluxStop® by a major insititution like Careggi underscores the growing clinical confidence and supports our strategy to scale the therapy across leading centers in Europe. We look forward to the impact this expansion will have for patients in Tuscany and beyond.”
1. Boulton KHA, Dettmar PW. A narrative review of the prevalence of gastroesophageal reflux disease (GERD). Ann Esophagus. 2022.
For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company’s Certified Adviser is FNCA Sweden AB, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on December 10, 2025, at 08:00 a.m. (CET).
